<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568175</url>
  </required_header>
  <id_info>
    <org_study_id>JR-141-301</org_study_id>
    <nct_id>NCT03568175</nct_id>
  </id_info>
  <brief_title>A Study of JR-141 in Patients With Mucopolysaccharidosis II</brief_title>
  <official_title>A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and&#xD;
      safety of study drug for the treatment of the MPS II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Heparan Sulfate Levels.</measure>
    <time_frame>Baseline, 24-26 weeks, 50-52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Dermatan Sulfate Levels.</measure>
    <time_frame>Baseline, 24-26 weeks, 50-52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Heparan Sulfate Levels.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Dermatan Sulfate Levels.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volumes.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volumes.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardiac Function.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-minute Walk Test Distance.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
    <description>Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Joint Range of Motion.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>Baseline to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>Baseline, 25 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001)</measure>
    <time_frame>25, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. )</measure>
    <time_frame>25, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentration in Cerebrospinal Fluid.</measure>
    <time_frame>25, 52*weeks</time_frame>
    <description>*Drug concentration in Cerebrospinal Fluid at 52 Weeks is applicable only for subjects to be enrolled in extension study .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>JR-141 2.0 mg/kg/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-141</intervention_name>
    <description>IV infusion, 2.0 mg/kg/week</description>
    <arm_group_label>JR-141 2.0 mg/kg/week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of providing written consent by himself (not mandatory for those aged under 20&#xD;
             years at the time of informed consent process, or those who is impossible to obtain&#xD;
             consent from the patient himself due to intellectual disabilities associated with MPS&#xD;
             II.)&#xD;
&#xD;
          2. In the case of a patient who is under the age of 20 years or from whom it is not&#xD;
             possible to obtain consent due to intellectual disabilities associated with MPS II, he&#xD;
             may be included if written consent can be provided by legal representative (however,&#xD;
             written consent should be obtained from the patient himself too, whenever possible)&#xD;
&#xD;
          3. Males with confirmed diagnosis of MPS II, based on deficient activity of&#xD;
             iduronate-2-sulfatase (IDS) in leucocytes, plasma or fibroblasts and/or pathogenic&#xD;
             mutations identified in the IDS gene, etc.&#xD;
&#xD;
          4. Na√Øve patients or patients who are receiving stable enzyme replacement therapy with&#xD;
             Elaprase for more than 8 weeks before the observational period starts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous engrafted HSCT, excluding those who need enzyme replacement therapy even&#xD;
             after HSCT.&#xD;
&#xD;
          2. Judged by the investigator or subinvestigator as being unable to undergo lumbar&#xD;
             puncture, including those who have difficulties in taking position for lumbar puncture&#xD;
             due to joint contracture or those who are likely experience difficulty breathing&#xD;
             during the lumbar puncture process.&#xD;
&#xD;
          3. Judged by the investigator or subinvestigator to be ineligible to participate in the&#xD;
             study due to a history of serious drug allergy or sensitivity.&#xD;
&#xD;
          4. Patients who have received other investigational product within 4 months before&#xD;
             enrollment in the study.&#xD;
&#xD;
          5. Otherwise judged by the investigator or subinvestigator to be ineligible to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fukui Clinical site</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site 2</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Clinical site</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Clinical site</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Clinical site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site 2</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okinawa Clinical site</name>
      <address>
        <city>Okinawa</city>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 3</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 2</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical site</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site 2</name>
      <address>
        <city>Shizuoka</city>
        <zip>426-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Clinical site</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical site</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori Clinical site</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/33038326/</url>
    <description>A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

